---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-26-000037"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2026-05-13T11:34:07+00:00"
generated_at: "2026-05-13T11:36:38.941040+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Altimmune Q1 net loss $22.6M; cash $535M; PERFORMA Phase 3 MASH trial initiation in H2 2026

## Summary
- Net loss of $22.6M ($0.18 loss per share) vs $19.6M ($0.26) in Q1 2025; R&D $16.2M, G&A $8.1M.
- Cash, equivalents and short-term investments $332M at Mar 31, 2026; $535M at Apr 30, 2026 after $225M public offering.
- Initiation of PERFORMA Phase 3 MASH trial planned for H2 2026; topline RECLAIM Phase 2 AUD data expected Q3 2026; RESTORE Phase 2 ALD enrollment completion Q3 2026.
- Pemvidutide received Breakthrough Therapy Designation for MASH; EASL presentations on May 28, 2026 including 48-week IMPACT data.

## SEC filing metadata
- accession: 0001326190-26-000037
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2026-05-13T11:34:07+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/0001326190-26-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-26-000037
- JSON: https://secwatch.observer/filing/0001326190-26-000037.json
- Plain text: https://secwatch.observer/filing/0001326190-26-000037.txt

## Key facts
- Earnings Releases
  Altimmune, Inc. reported the first quarter ended March 31, 2026 results: net income $22.6 million, or $0.18 net loss per share.
  - Period: the first quarter ended March 31, 2026
  - Net income: $22.6 million, or $0.18 net loss per share
  - Result: reported results
  source text: Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/0001326190-26-000037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.